[go: up one dir, main page]

RU93054017A - METHOD FOR TREATING OSTEOPOROSIS, COMPOSITION FOR TREATING OSTEOPOROSIS, APPLICATION OF ACTIVE PHOSPHONATE AND ESTROGENIC HORMONE FOR TREATING OSTEOPOROSIS - Google Patents

METHOD FOR TREATING OSTEOPOROSIS, COMPOSITION FOR TREATING OSTEOPOROSIS, APPLICATION OF ACTIVE PHOSPHONATE AND ESTROGENIC HORMONE FOR TREATING OSTEOPOROSIS

Info

Publication number
RU93054017A
RU93054017A RU93054017/14A RU93054017A RU93054017A RU 93054017 A RU93054017 A RU 93054017A RU 93054017/14 A RU93054017/14 A RU 93054017/14A RU 93054017 A RU93054017 A RU 93054017A RU 93054017 A RU93054017 A RU 93054017A
Authority
RU
Russia
Prior art keywords
treating osteoporosis
composition
application
active phosphonate
estrogenic hormone
Prior art date
Application number
RU93054017/14A
Other languages
Russian (ru)
Other versions
RU2113848C1 (en
Inventor
Элэйн МакОскер Жослин
Original Assignee
Норвич Итон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Норвич Итон Фармасьютикалз, Инк. filed Critical Норвич Итон Фармасьютикалз, Инк.
Priority claimed from PCT/US1992/000854 external-priority patent/WO1992014474A1/en
Publication of RU93054017A publication Critical patent/RU93054017A/en
Application granted granted Critical
Publication of RU2113848C1 publication Critical patent/RU2113848C1/en

Links

Claims (1)

Способы лечения остеопороза у человека или других животных, включающие введение активно действующего на кости фосфоната указанному субъекту в количестве по крайней мере около 0,1 LED и эстрогенного гормона в количестве от около 0,2 до около 0,8 LED в день в течение указанного курса лечения. Активно действующим на кости фосфонатом является предпочтительно бисфосфонат или фосфоноалкилфосфонат.Methods of treating osteoporosis in humans or other animals, comprising administering an active bone phosphonate to said subject in an amount of at least about 0.1 LED and estrogen hormone in an amount of about 0.2 to about 0.8 LED per day for the course treatment. The active phosphonate on the bone is preferably a bisphosphonate or phosphonoalkylphosphonate.
RU93054017A 1991-02-26 1992-01-31 Method of osteoporosis treatment, composition for osteoporosis treatment, use of phosphonate and estrogenic hormone acting on bone for osteoporosis treatment RU2113848C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66177791A 1991-02-26 1991-02-26
US661,777 1991-02-26
PCT/US1992/000854 WO1992014474A1 (en) 1991-02-26 1992-01-31 Methods for the treatment of osteoporosis

Publications (2)

Publication Number Publication Date
RU93054017A true RU93054017A (en) 1997-01-27
RU2113848C1 RU2113848C1 (en) 1998-06-27

Family

ID=24655074

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93054017A RU2113848C1 (en) 1991-02-26 1992-01-31 Method of osteoporosis treatment, composition for osteoporosis treatment, use of phosphonate and estrogenic hormone acting on bone for osteoporosis treatment

Country Status (18)

Country Link
US (1) US6329354B1 (en)
EP (1) EP0573604B1 (en)
JP (1) JP3727332B2 (en)
KR (1) KR100240358B1 (en)
AT (1) ATE119777T1 (en)
AU (1) AU664368B2 (en)
CA (1) CA2101275C (en)
CZ (1) CZ282609B6 (en)
DE (1) DE69201725T2 (en)
DK (1) DK0573604T3 (en)
ES (1) ES2069424T3 (en)
HU (1) HU215124B (en)
IE (1) IE65963B1 (en)
NO (1) NO305581B1 (en)
NZ (1) NZ241717A (en)
RU (1) RU2113848C1 (en)
SK (1) SK90093A3 (en)
WO (1) WO1992014474A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2119337C1 (en) * 1992-03-21 1998-09-27 Энтек Гезельшафт фюр Эндокринологише Технологи мбХ Transdermal preparation of the prolonged effect showing antiosteoporotic activity
JPH08502287A (en) * 1992-10-09 1996-03-12 ジ・アップジョン・カンパニー Pyrimidine bisphosphonates and (alkoxymethylphosphinyl) alkylphosphonic acids as anti-inflammatory agents
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
EP0675723A4 (en) * 1992-12-23 1998-08-05 Merck & Co Inc Bisphosphonate/estrogen therapy for treating and preventing bone loss.
DE59300688D1 (en) * 1993-05-15 1995-11-02 Boehringer Mannheim Gmbh Tablet with improved bioavailability containing dichloromethylene diphosphonic acid as active ingredient.
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
AR000555A1 (en) * 1994-12-28 1997-07-10 Gador Sa Use of anabolic compositions for bone mass based on effective non-toxic amounts of Ä3- (n, n-dimethylamino) -1-hydroxypropylidene-bisphosphonic acid or the monosodium salt or other pharmaceutically acceptable salt thereof
DE19635883A1 (en) * 1996-09-04 1998-03-05 Lohmann Therapie Syst Lts Transdermal therapeutic system with an active ingredient combination containing estriol
WO1998023274A1 (en) * 1996-11-25 1998-06-04 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
AR013994A1 (en) * 1998-10-30 2001-01-31 Gador Sa PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES.
US6579860B1 (en) * 1998-12-25 2003-06-17 Toray Industries, Inc. Interleukin-6 production inhibitors
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US6653298B2 (en) 2000-01-14 2003-11-25 Sterix Limited Composition
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
NZ584219A (en) * 2007-11-30 2012-03-30 Novartis Ag C2-c5-alkyl-imidazole-bisphosphonates
PL2459176T3 (en) 2009-07-31 2018-02-28 Grünenthal GmbH Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553314A (en) 1968-12-23 1971-01-05 Procter & Gamble Oral compositions for calculus retardation
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
EP0088462A3 (en) * 1982-03-01 1984-06-06 The Procter & Gamble Company Anti-inflammatory and rheumatic composition containing organophosphonate and steroid
EP0162510B1 (en) * 1984-04-30 1991-08-28 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL86951A (en) 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkyl-phosphinates and pharmaceutical compositions containing them

Similar Documents

Publication Publication Date Title
RU93054017A (en) METHOD FOR TREATING OSTEOPOROSIS, COMPOSITION FOR TREATING OSTEOPOROSIS, APPLICATION OF ACTIVE PHOSPHONATE AND ESTROGENIC HORMONE FOR TREATING OSTEOPOROSIS
NO933044D0 (en) PROCEDURE FOR TREATING OSTEOPOROSIS
DE69008476D1 (en) Pharmaceutical composition for the treatment of osteoporosis.
FI932385A0 (en) Behandling of the osteoporos genome by anatomical use of somatoliberin (GRF) in combination with parathyroid hormone (PTH)
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
RU2002130192A (en) METHOD FOR TREATING OR PREVENTING OBESITY
ZA878652B (en) Agents for combating pests and plant treatment agents
ATE110958T1 (en) USING SERTRALINE TO TREAT PREMATURE EJACULATION.
DE69501419D1 (en) Pharmaceutical composition for the treatment of osteoporosis containing xanthohumol
DE69826132D1 (en) PHARMACEUTICAL COMBINATION OF PARATHORMONE AND AN INHIBITOR OF BONE RESORPTION
DK586387A (en) PIPERIDE INGREDIENTS FOR TREATMENT OF PAIN CONDITIONS
DE69316013D1 (en) USE OF PHOSPHINATE FOR TREATING OSTEOPOROSIS
DE69420776D1 (en) Compositions containing idebenone for the treatment of M. Alzheimer's
CA2074166A1 (en) Method for treating intestinal diseases
ATE88633T1 (en) USE OF CERTAIN CALCIUM CITRATE MALATE IN THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF OSTEOPOROSIS.
DE68919673D1 (en) METHOD FOR TREATING AND PREVENTING LOSS OF BONE MASS.
KR970705400A (en) METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE USING BONE ACTIVE PHOSPONATE AND PARTHROPHONE HORMONE
KR970705397A (en) ESTROGENS AND PARATHYROID HORMONE FOR TREATING OSTEOPOROSIS
PE48597A1 (en) METHOD FOR THE TREATMENT OF OSTEOPOROSIS USING ANTIRESORBENT COMPOUNDS AND PARATHYROID HORMONE
ATE306278T1 (en) TREATING BONE DISEASES WITH ADRENOMEDULLIN
IL82279A0 (en) Fumigant method and compositions comprising 2,2-dibromo-3-nitrilopropionamide for treating crops
CO4700476A1 (en) METHOD FOR THE TREATMENT OF OSTEOPOROSIS USING ANTIRESORPTIVE COMPOUNDS AND PARATHYROID HORMONES
AR001226A1 (en) Methods for the treatment of osteoporosis using active phosphonates and parathyroid hormone
CO4410200A1 (en) METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING ACTIVE BONE PHOSPHONATES AND PARATHYROID HORMONES
RU96100080A (en) TREATMENT OF CONDITIONS RELATED TO VIOLATION OF THE PARATHORMONE HARMONIA